FCGR2A and neoplasm: FcγR engagement of immune complexes (ICs) by DCs induces their CCR-7 dependent migration to LNs (Clatworthy et al., 2014), and we have shown that the combination of DC adjuvants with tumor-bound allogeneic antibody ICs induce robust anti-tumor T cell responses (Carmi et al., 2015).